Literature DB >> 3491156

Experimental allergic encephalomyelitis mediated by murine encephalitogenic T cell lines specific for myelin proteolipid apoprotein.

J Satoh, K Sakai, M Endoh, F Koike, T Kunishita, T Namikawa, T Yamamura, T Tabira.   

Abstract

T cell lines specific for bovine myelin proteolipid apoprotein (PLP) were established from SJL/J mice. The line cells bore surface phenotypes of T helper/inducer cells (Lyt-1+, Lyt-2-, L3T4+) and responded well to bovine, rat, and guinea pig PLP but not to myelin basic protein. One line responded to major PLP, and another responded to both major PLP and DM-20, which are the two major intrinsic membrane proteins of the central nervous system (CNS) myelin. Intraperitoneal inoculation of 4 to 30 X 10(6) PLP-activated line cells followed by injection of pertussis vaccine induced acute inflammatory disease of the CNS, with typical clinical signs of EAE mostly in a week in recipient mice that had been treated with low-dose irradiation. Almost all animals recovered completely, and two of the 12 animals relapsed 42 or 75 days after inoculation. The lesions were restricted to the CNS and were characterized by perivascular and parenchymal infiltration of inflammatory cells, fibrin deposit, and demyelination. In the severe lesions, axons were also damaged. These observations suggest that PLP is a definite encephalitogen, and PLP-sensitized effector T cells induce inflammatory demyelination in the CNS.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3491156

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  The myelin basic protein gene is not a major susceptibility locus for multiple sclerosis in Italian patients.

Authors:  M Eoli; M Pandolfo; C Milanese; P Gasparini; A Salmaggi; M Zeviani
Journal:  J Neurol       Date:  1994-10       Impact factor: 4.849

2.  A history of proteolipids: a personal memoir.

Authors:  M B Lees
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

3.  The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease.

Authors:  A Ben-Nun; I Mendel; R Bakimer; M Fridkis-Hareli; D Teitelbaum; R Arnon; M Sela; N Kerlero de Rosbo
Journal:  J Neurol       Date:  1996-04       Impact factor: 4.849

4.  Induction of apoptosis in human mitogen-activated peripheral blood T-lymphocytes by the ether phospholipid ET-18-OCH3: involvement of the Fas receptor/ligand system.

Authors:  C Cabaner; C Gajate; A Macho; E Muñoz; M Modolell; F Mollinedo
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

5.  Adoptively transferred experimental allergic encephalomyelitis in chimeric rats: identification of transferred cells in the lesions of the central nervous system.

Authors:  Y Matsumoto; M Fujiwara
Journal:  Immunology       Date:  1988-09       Impact factor: 7.397

6.  Localization of interferon-gamma and Ia-antigen in T cell line-mediated experimental autoimmune encephalomyelitis.

Authors:  G Stoll; S Müller; B Schmidt; P van der Meide; S Jung; K V Toyka; H P Hartung
Journal:  Am J Pathol       Date:  1993-06       Impact factor: 4.307

Review 7.  MS as autoimmune disease: myelin antigens.

Authors:  W Fierz
Journal:  Res Immunol       Date:  1989-02

8.  Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein.

Authors:  N Kerlero de Rosbo; R Milo; M B Lees; D Burger; C C Bernard; A Ben-Nun
Journal:  J Clin Invest       Date:  1993-12       Impact factor: 14.808

9.  Myelin antigen reactive T cells in cerebrovascular diseases.

Authors:  W Z Wang; T Olsson; V Kostulas; B Höjeberg; H P Ekre; H Link
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

10.  Cross-sectional and longitudinal analysis of myelin-reactive T cells in patients with multiple sclerosis.

Authors:  Jan D Lünemann; Sandra Rückert; Florian Kern; Uwe Wendling; Ruud van der Zee; Hans D Volk; Frauke Zipp
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.